Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage IV non-small cell lung cancer (NSCLC) that has spread outside the lung.
- Your cancer does not have the EGFR, ALK, or ROS1 gene changes (called 'wild-type').
- You received immunotherapy as your first treatment and it worked for at least 3 months.
- You have a tumor that can be measured on a CT scan and hasn't been treated with radiation or freezing.
- You are well enough to be up and about (ECOG score 0–2) and have adequate organ function (like blood counts, liver, kidneys).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
This trial tests a new combination for advanced lung cancer: an immunotherapy drug (tislelizumab) plus standard chemotherapy, and adds a common allergy medicine (diphenhydramine) to see if it improves outcomes. It's for people who haven't had prior systemic treatment for their lung cancer and are generally healthy.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.